Related Experiment Video

Updated: Jun 20, 2026

Quantitative Immunofluorescence to Measure Global Localized Translation
09:13

Quantitative Immunofluorescence to Measure Global Localized Translation

Published on: August 22, 2017

Translational research in phase I trials

Angelica Fasolo1, Cristiana Sessa

  • 1Medical Oncology, Montabone Unit for New Drugs Development, Istituto Nazionale Tumori Milano, Milan, Italy. angelica.fasolo@istitutotumori.mi.it

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|September 25, 2009
PubMed

Insights

Translational research (TR) bridges preclinical findings and clinical practice. Biomarkers are crucial for developing targeted cancer therapies by validating drug efficacy and guiding treatment strategies.

Area of Science:

  • Oncology
  • Pharmacology
  • Biomarker Discovery

Background:

  • Translational research (TR) aims to translate preclinical findings into clinical applications.
  • TR involves studying disease biology and drug effects in preclinical models and humans.
  • Developing new cancer targeted therapies is a key focus of TR.

Purpose of the Study:

  • To review the role of biomarkers in advancing targeted cancer therapy development.
  • To highlight how biomarkers facilitate rational drug design and testing.
  • To emphasize the importance of biomarker discovery and validation in TR.

Main Methods:

  • Literature review focusing on biomarker contributions to targeted therapy.
  • Analysis of biomarker definition and function in drug development.
  • Examination of biomarker application in preclinical and clinical settings.

Main Results:

  • Biomarkers are essential for the rational development of targeted agents.
  • Biomarker validation provides mechanistic insights into drug effects.
  • TR leverages biomarkers throughout the drug discovery and clinical testing pipeline.

Conclusions:

  • Biomarkers are pivotal in accelerating the development of novel targeted cancer therapies.
  • Effective use of biomarkers ensures a mechanistic approach to drug development.
  • Continued focus on biomarker discovery and validation is critical for TR success.

More Related Videos

Xenopus laevis as a Model to Identify Translation Impairment10:24

Xenopus laevis as a Model to Identify Translation Impairment

Published on: September 27, 2015

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Phase I Oxidative Reactions: Overview01:19

Phase I Oxidative Reactions: Overview

Phase I biotransformation, or functionalization, is a crucial chemical process that converts drugs and other xenobiotics into more water-soluble forms, facilitating expulsion from the body. It involves oxidative, reductive, and hydrolytic reactions that add or unveil polar functional groups on lipophilic substrates. Key players in phase I reactions are the mixed-function oxidases. Situated in liver cell microsomes, these enzymes predominantly carry out drug metabolism. They require molecular...
Leaky Scanning02:28

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R stands for...